News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Partner Pronova BioPharma Wins Lovaza Patent Case Against Teva Pharmaceutical Industries Limited (TEVA) & Par Pharmaceutical, Inc.


5/31/2012 7:38:43 AM

GlaxoSmithKline plc (GSK) has confirmed that US District Judge Sue Lewis Robinson, the presiding judge in the US District Court for the District of Delaware, ruled in Pronova’s favour in Pronova’s patent litigation involving US Patent Nos. 5,656,667 (“’667 patent”) and 5,502,077 (“’077” patent) covering Lovaza. GSK already has marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico. The Court found Pronova’s patent claims are valid and would be infringed by Teva Pharmaceuticals USA, Inc. and Par Pharmaceutical Inc.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES